Yazar "Sevindik, Ömür Gökmen" için listeleme
-
Idarubicin versus daunorubicin versus mitoxantrone for induction chemotherapy in acute myeloid leukemia: Patient registration study of Turkish society of hematologyacute myeloid leukemia working group
Pınar, İbrahim Ethem; Çelik, Serhat; Polat, Merve Gökçen; Karataş, Aylin Fatma; Doğan, Ali; Iltar, Utku; Cengiz Seval, Güldane; Sevindik, Ömür Gökmen (American Society of Hematology, 2023)Introduction: Standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) includes a combination of standard-dose cytarabine and an anthracycline (idarubicin [IDA], daunorubicin [DNR], or mitoxantrone ... -
Inherited transmission of the CSF3R T618I mutation: A familial report
Serin, istemi; Cinli, Tahir Alper; Tunç, Sertaç; Kaynar, Leylagül; Sevindik, Ömür Gökmen; Yokuş, Osman (Springer, 2023)To the editor, Chronic neutrophilic leukemia (CNL) is a rare, break cluster region-Abelson 1 (BCR-ABL1) negative myeloproliferative neoplasm, which is characterized by mature neutrophilic proliferation with neutrophilic ... -
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; İpek, Yıldız; Gedük, Ayfer; Harmandalı, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kasar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (CIG Media Group, 2021)Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ... -
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; Yıldız, İpek; Gedük, Ayfer; Harmandali, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kaşar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (American Society of Hematology, 2021)... -
Is the end close for the graft-versus-host disease that is a big problem following allogeneic hematopoetic stem cell transplantation?
İlhan, Osman; Cengiz Seval, Güldane; Özkurt, Zübeyde Nur; Ural, Ali Uğur; Aylı, Meltem; Sevindik, Ömür Gökmen; Civriz Bozdağ, Sinem; Kurt Yüksel, Meltem; Gülbaş, Zafer; Özcan, Muhit (American Society of Hematology, 2018)… -
Is the platelet-to-lymphocyte ratio a new prognostic marker in multiple myeloma?
Solmaz, Şerife; Uzun, Özcan; Acar, Celal; Sevindik, Ömür Gökmen; Pişkin, Özden; Özsan, Hayri Güner; Demirkan, Fatih; Ündar, Bülent; Alacacıoğlu, Ahmet; Özcan, Mehmet Ali; Alacacıoğlu, İnci (Wolters Kluwer Medknow Publications, 2018)BACKGROUND: Recent reports showed neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR), as a predictor of progression-free survival (PFS) and overall survival ... -
Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study
Mateos, Maria-Victoria; Rodriguez Otero, Paula; Koh, Youngil; Martinez-Lopez, Joaquin; Parmar, Gurdeep; Prince, H. Miles; Quach, Hang; Ribas, Paz; Hermansen, Emil; Hungria, Vania T. M.; Kalayoğlu Beşışık, Sevgi; Kim, Jin Seok; Leleu, Xavier; Peceliunas, Valdas; Schjesvold, Fredrik; Sevindik, Ömür Gökmen; Lavrova, Tatiana; Dubin, Franck; Devisme, Christine; Lepine, Lucie; Ghobrial, Irene (American Society of Hematology, 2022)Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients ... -
Mutation profile of the patients diagnosed with myeloid neoplasia tested with next generation sequencing and clinical implications
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Ayaz, Akif; Seca, Fatma; Sevindik, Ömür Gökmen (Inonu University Faculty of Medicine, 2022)Aim: To analyze the distribution of gene mutations in myeloid neoplasias, based on next generating sequencing technology (NGS) and evaluate their clinical implications and impact on the risk stratification. Materials and ... -
Otolog kök hücre transplantasyonunda Sitomegalovirüs (CMV) ve Hepatit B (HBV) reaktivasyonu: Tek merkez deneyimi
Gemici, Aliihsan; Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Sadri, Sevil; Serin, İstemi; Erol, Vedat Buğra; Sargın, Fatma Deniz; Kaynar, Leylagül (Lösemi Lenfoma Miyelom Derneği, 2022)Amaç: Sitomegalovirüs (CMV) reaktivasyonu allojenik hematopoetik kök hücre transplantasyo- nu sırasında sık görülür. Hepatit B reaktivasyonu (HBV), akut hepatit ve fulminan karaciğer yet- mezliği veya sadece HBV DNA düzeyinde ... -
Pegaspargase, venetoclax, and nelarabine: A successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient
Yiğit Kaya, Süreyya; Bektaş, Şebnem; Aşkın, Abdullah Emre; Balık Aydın, Berrin; Mutlu, Yaşa Gül; Sevindik, Ömür Gökmen (Springer, 2023)... -
Persistent polyclonal B-Cell lymphocytosis with binucleated lymphocytes
Balık Aydın, Berrin; Mutlu, Yaşa Gül; Sevindik, Ömür Gökmen (Galenos Yayıncılık, 2021)A 46-year-old female was admitted to our clinic suffering from long-standing leukocytosis. She was evaluated at another hospital regarding this lymphocytic leukocytosis (absolute lymphocyte count: 10770/µL) with no final ... -
Plerixafor in autologous stem cell transplantation: Does it affect engraftment kinetics?
Serin, İstemi; Sevindik, Ömür Gökmen; Balık Aydın, Berrin; Melek, Elif; Mutlu, Yaşa Gül; Bilgen, Hülya; Beköz, Hüseyin; Kaynar, Leylagül (Elsevier Ltd, 2023)Plerixafor increases stem cell mobilization by reversibly binding to the chemokine receptor CXCR4. In our study, we examined the results of mobilization with plerixafor and granulocyte colony-stimulating factor (G-CSF) and ... -
Prognostic factors and intensive care outcome in post-transplant phase of hematopoietic stem cell transplantation intensive care outcome in hematopoietic stem cell transplantation
Mutlu, Yaşa Gül; Balık Aydın, Berrin; Erdoğan, Cem; Kızılaslan, Deniz; Beköz, Hüseyin Saffet; Gemici, Aliihsan; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Springer India, 2023)Introduction To identify new clinical and biologic parameters associated with short-term survival in allogeneic or autologous hematopoietic stem cell transplantation (HSCT) patients who were admitted to the intensive care ... -
Quality of life assessment with EORTC QLQ in patients with hodgkin lymphoma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Sevindik, Ömür Gökmen (Ankara Hematology Oncology Association, 2022)Aim: The aim of our study is to obtain data on the quality of life (QoL) in Hodgkin lymphoma (HL) patients in a representative sample of the general population of Turkey with the help of the EORTC QLQ-C30 and QLQ-HL27 ... -
Quality of life assessment with EORTC QLQ in patients with multiple myeloma: Multicenter study
Gemici, Aliihsan; Serin, İstemi; Erol, Vedat Buğra; Doğu, Mehmet Hilmi; İnce, İdris; Eren, Rafet; Tekinalp, Atakan; Karakuş, Volkan; Koç Erol, İklil Nur; Arslan, Zeynep Ece; Tay, Zekiye Nur; Tuncer, Elif Nur; Sevindik, Ömür Gökmen (Galenos Publishing House, 2022)Objective: Both the length of the treatment period and the diversity of the agents used in the treatment significantly affect the quality of life (QoL) of the patients with multiple myeloma (MM). With the aid of the EORTC ... -
A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
Gemici, Aliihsan; Özkalemkaş, Fahir; Doğu, Mehmet Hilmi; Tekinalp, Atakan; Alacacıoğlu, İnci; Güney, Tekin; İnce, İdris; Gedük, Ayfer; Akgün Çağlıyan, Gülsüm; Maral, Senem; Serin, İstemi; Gündüz, Eren; Karakuş, Volkan; Beköz, Hüseyin Saffet; Eren, Rafet; Pınar, İbrahim Ethem; Güneş, Ahmet Kürşad; Sargın, Fatma Deniz; Sevindik, Ömür Gökmen (CIG Media Group, 2021)Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients ... -
Real-world data from the Turkish national chronic lymphocytic leukemia registry
Demirkan, Fatih; Sevindik, Ömür Gökmen (CIG Media Group, 2020)Objective: We have previously established a nationwide registry to obtain real-world data to document the demographics and treatment outcomes of Turkish CLL patients. Patients or other participants: Patients who were ... -
Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: First reported case
Mutlu, Yaşa Gül; Yiğit Kaya, Süreyya; Maral, Senem; Melek, Elif; Başlar, Zafer; Kaynar, Leylagül; Sevindik, Ömür Gökmen (Frontiers Media SA, 2023)Central nervous system (CNS) involvement in multiple myeloma (MM) is a rare and challenging complication associated with poor prognosis and limited treatment options. Emerging T-cell directing therapies, such as bispecific ...